Clinical and Immunological Aspects of the Use of Monoclonal Antibodies in the New Coronavirus Infection Covid-19
DOI:
https://doi.org/10.48112/acmr.v3i4.43Keywords:
Monoclonal Antibodies, Interleukin-6, Covid-19Abstract
Abstract Views: 38
To date, methods of prevention and treatment of coronavirus infections have not been developed in essence. One of the reasons for this situation may be the peculiarities of the pathogenesis of coronavirus infection and the rapid development of the pandemic, which could hinder the effectiveness of ongoing research. As with any viral infection, with the development and spread of the inflammatory process, viremia develops, that is, the generalization of infection, cytokine secretion becomes uncontrolled, and the concentration of IFNy, IL-1, IL-6, IL-12 in the blood serum significantly increases, in other words, the primary inflammatory reaction enters a new phase — the cytokine storm phase, which manifests itself violently even according to clinical and laboratory parameters. In this regard, adequate therapy aimed at stopping the uncontrolled process induced not so much by viremia as by the associated inflammation is crucial. In this regard, the aim of our study was to study the effect of monoclonal antibodies, in particular the drug "Kazirivimab + Imdevimab"— a combination of recombinant monoclonal antibodies directed against S-protein on the clinical course and laboratory data in patients with a new coronavirus infection –Covid-19.
References
Sokolova TM, Poloskov VV, Shuvalov AN, Burova OS, Sokolova ZA. Signal TLR / RLR mechanisms of immunomodulatory action of ingavirin and thymogen preparations // Russian. Biotherapeutic J. 2019;18(1):60-66.
Aguiar JA, Tremblay BJ, Mansfield MJ, Woody O, Lobb B, Banerjee A, et al. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur Respir J. 2020;56(3):2001123. doi: 10.1183/13993003.01123-2020.
Anastassopoulou C, Russo L, Tsakris A, Siettos C. Data-based analysis, modelling and forecasting of the COVID-19 outbreak. PLoS One. 2020;15(3):e0230405. doi: 10.1371/journal.pone.0230405.
Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. Swiss Med Wkly. 2020;150:w20203. doi: 10.4414/smw.2020.20203.
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548. doi: 10.1172/JCI138003.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9.
Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20(25):7-13. doi: 10.2807/1560-7917.es2015.20.25.21163.
Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun. 2020;11(1):3924. doi: 10.1038/s41467-020-17834-w.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0.
Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med. 2020;23(4):268-271. doi: 10.34172/aim.2020.09.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi: 10.1183/13993003.00607-2020.
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10-18. doi: 10.12932/AP-200220-0773.
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76.
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-280. doi: 10.1111/tmi.13383.
Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi: 10.1038/s41467-020-16256-y.
Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2021;51(4):1107-1110. doi: 10.1007/s11239-020-02105-8.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Advances in Clinical Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI-PMH 
